Raymond James Upgrades ProQR Therapeutics to Strong Buy, Raises Price Target to $14
Portfolio Pulse from Benzinga Newsdesk
Raymond James analyst Steven Seedhouse has upgraded ProQR Therapeutics from Outperform to Strong Buy and increased the price target from $6 to $14.
October 29, 2024 | 1:27 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Raymond James has upgraded ProQR Therapeutics to Strong Buy and increased the price target to $14, indicating strong confidence in the company's future performance.
The upgrade to Strong Buy and significant increase in price target from $6 to $14 by a reputable analyst suggests a positive outlook for ProQR Therapeutics. This is likely to attract investor interest and potentially drive the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100